Sanofi diabetes med offers freer schedule

Share this article:

New Phase-IIIb data about Sanofi's diabetes drug Lyxumia (lixisenatide) show that the drug may have flexible dosing on its side. The drug met the target of “non-inferiority in blood-sugar lowering” regardless of whether it was taken before breakfast or during what Sanofi calls “the main meal of the day,” which ended up being lunch for 53% of the patients in the 451-person clinical trial.

The daily GLP-1 injection is already marketed in Europe, Mexico, Australia and Japan, among other countries, but is in waiting mode in the US. The company pulled its FDA review request in September, saying it wanted its Elixa cardiovascular study to be completely wrapped before offering the drug up for US regulatory review.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.